BRAF and hepatocellular carcinoma: For instance, in non-small cell lung cancer (NSCLC), the combination of Bevacizumab with chemotherapy is recommended for patients without EGFR or ALK gene mutations.460 In patients with metastatic colorectal cancer (CRC), Bevacizumab is also used in conjunction with chemotherapy, especially for those with tumors of KRAS, NRAS, and BRAF wild-type status.461 Additionally, for patients with advanced hepatocellular carcinoma (HCC), the combination therapy of Bevacizumab with the immune checkpoint inhibitor Atezolizumab is a first-line option.